胰腺神经内分泌肿瘤淋巴结受累的预后作用及预测因素
本研究纳入2009至2019年在本院接受根治性手术切除且术前有CT的236例胰腺神经内分泌肿瘤患者,分析淋巴结受累(LNI)的预后作用及术前影像预测因素。44例(18.6%)存在LNI。胆胰管扩张、肿瘤边缘不规则及WHO分级G2/G3是LNI的独立危险因素;LNI、G3及胆胰管扩张与术后复发相关。LNI患者无病生存期显著更差(3年DFS 85.9% vs 96.7%,5年DFS 65.1% vs 93.9%,P<0.001)。
要点
- 术前CT见胆胰管扩张或肿瘤边缘不规则时,应警惕淋巴结受累风险。
- WHO分级G2/G3是LNI独立危险因素,G3风险最高(OR 12.067)。
- LNI患者3年及5年DFS显著低于无LNI者,报告应提示淋巴结状态。
核心结论
- 淋巴结受累与胰腺神经内分泌肿瘤患者无病生存期降低相关。
- 胆胰管扩张、肿瘤边缘不规则及WHO分级G2/G3是淋巴结受累的独立危险因素。
- 淋巴结受累、G3及胆胰管扩张与术后肿瘤复发独立相关。
研究设计与样本
- 单中心回顾性研究,纳入2009至2019年本院236例术前接受CT检查并行根治性手术切除的胰腺神经内分泌肿瘤患者。
- 采用单因素及多因素logistic回归分析淋巴结受累及肿瘤复发的危险因素,比较有无淋巴结受累者的无病生存率。
诊断标准与关键数值
- 胆胰管扩张预测淋巴结受累的OR为2.295(95%CI 1.046-5.035,P=0.038)。
- 肿瘤边缘预测淋巴结受累的OR为2.189(95%CI 1.034-4.632,P=0.041)。
- WHO分级G2预测淋巴结受累的OR为2.923(95%CI 1.005-8.507,P=0.049),G3的OR为12.067(95%CI 3.057-47.629,P<0.001)。
- 淋巴结受累预测肿瘤复发的OR为2.728(95%CI 1.070-6.954,P=0.036),G3的OR为4.894(95%CI 1.047-22.866,P=0.044),胆胰管扩张的OR为2.895(95%CI 1.124-7.458,P=0.028)。
- 有淋巴结受累者3年DFS为85.9% vs 96.7%(P<0.001),5年DFS为65.1% vs 93.9%(P<0.001)。
临床应用与阅片要点
- 阅片时关注术前CT上胆胰管扩张及肿瘤边缘不规则,作为淋巴结受累的影像预警征象。
- 报告胰腺神经内分泌肿瘤时应描述肿瘤边缘及胆胰管状态,并结合WHO分级提示淋巴结受累风险。
- 对存在淋巴结受累风险的患者,报告中可提示预后可能较差及术后复发风险。
局限性
- 单中心回顾性研究,样本来自单一医院,结果外推需谨慎。
- 仅纳入有术前CT且接受根治性手术的患者,存在选择偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To define the prognostic role of lymph node involvement (LNI) in patients with pancreatic neuroendocrine tumors (PNETs) and identify predictors of LNI using a comprehensive multifactor analysis focusing on preoperative radiological features.
METHODS: This study included 236 patients with preoperative computed tomography who underwent radical surgical resection of PNETs at our hospital between 2009 and 2019. Univariate and multivariable logistic regression analyses were performed to investigate the risk factors associated with LNI and tumor recurrence. The disease-free survival (DFS) rates with and without LNI were compared.
RESULTS: Forty-four of the 236 patients (18.6%) had LNI. Biliopancreatic duct dilatation (odds ratio [OR], 2.295; 95% confidence interval [CI], 1.046-5.035; p = 0.038), tumor margin (OR, 2.189; 95% CI, 1.034-4.632; p = 0.041), and WHO grade (G2: OR, 2.923; 95% CI, 1.005-8.507; p = 0.049; G3: OR, 12.067; 95% CI, 3.057-47.629; p < 0.001) were independent risk factors of LNI in PNETs. Multivariable analysis showed that LNI (OR, 2.728; 95% CI, 1.070-6.954; p = 0.036), G3 (OR, 4.894; 95% CI, 1.047-22.866; p = 0.044), and biliopancreatic duct dilatation (OR, 2.895; 95% CI, 1.124-7.458; p = 0.028) were associated with PNET recurrence in patients after surgery. Patients with LNI had a significantly worse DFS than those without LNI (3-year DFS: 85.9 vs. 96.7%; p < 0.001; 5-year DFS: 65.1 vs. 93.9%; p < 0.001).
CONCLUSION: LNI was associated with decreased DFS. Biliopancreatic duct dilatation, irregular tumor margins, and grades G2 and G3 were independent risk factors for LNI.
引用
- Ren, Tan, Cao, et al. Prognostic role and predictors of lymph node involvement in pancreatic neuroendocrine tumors. Eur J Radiol. 2023. PMID: 36940547. doi:10.1016/j.ejrad.2023.110772
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。